INTRODUCTION
The innate immune response to the invasion of microorganisms can trigger a pathophysiological cascade of events culminating in severe sepsis and septic shock in humans. [1] [2] [3] As the interface between these microbial components and the innate immune system, CD14 is believed to play a key role in the pathogenesis of sepsis. 2, 3 CD14 is a receptor for components of numerous microorganisms including Gram-negative bacteria, Gram-positive bacteria, mycobacteria, and fungi 4 and is expressed on myeloid cells and is abundant in plasma. 3 CD14 functions as an extracellular sensor for microbial components. The downstream consequences of CD14 recognition of microbial components include signal transduction through the Toll-like receptors (TLRs), 1, 3, 5 cell activation, and release of cytokines, lipid mediators, coagulation factors, and reactive intermediates. 2, [6] [7] [8] In cases of localized infections, this cascade of events functions to isolate, kill, and clear invading micro-organisms. However, in some cases, this same cascade of events can result in a systemic inflammatory response leading to severe sepsis, septic shock, multiple organ failure, and death 8 An overview and discussion of clinical studies with IC14, a chimeric monoclonal antibody directed against human CD14 is presented here. These studies include phase 1 trials in: (i) healthy subjects; (ii) healthy subjects challenged with lipopolysaccharide (LPS); and (iii) patients with severe sepsis. In addition, a discussion of recent non-clinical studies describing the effect of an anti-CD14 antibody on bacterial clearance is also presented.
NON-CLINICAL STUDIES
The ability of anti-CD14 monoclonal antibodies to prevent mortality and disease progression in endotoxin-induced animal models of sepsis are described in detail elsewhere. 9, 10 In general, the results of these studies demonstrate that anti-CD14 attenuates the release of pro-inflammatory cytokines, reduces organ pathology, and prevents septic shock and mortality.
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In the last few years, several studies performed in Gramnegative infection models have indicated that CD14-specific antibodies impair the host response to bacteria leading to reduced bacterial clearance and infectious complications in the absence of antimicrobial therapy. The results of these studies suggest that administration of anti-CD14 to patients infected with Gram-negative organisms may increase their risk of developing secondary infection in the absence of appropriate antimicrobial therapy. 11, 12 In contrast, CD14 knockout mice appear to clear Gram-negative organisms without any sequelae. 13 In an effort to resolve these apparent contradictions, the effect of an anti-CD14 antibody on bacterial clearance in the presence or absence of antimicrobial therapy was assessed using a rabbit bacterial clearance model. 14 Briefly, rabbits were treated intravenously (i.v.) with either an anti-CD14 antibody (1116.1a6, 5 mg/kg) or an isotype-matched control antibody (W6-32) 30 min prior to administration of a serum-resistant, highly virulent strain of Escherichia coli (10 6 CFU) that was initially isolated from the cerebrospinal fluid of a human neonate with Gram-negative bacillary meningitis. Each animal was treated with either ceftazidime (50 mg/kg, i.m.) or placebo 30 min after bacterial challenge. Serial blood culture determinations were performed and quantitative colony counts in lung, liver, spleen, and kidney were assessed 24 h after microbial challenge.
The results of this study indicate that an anti-CD14 antibody did not adversely affect bacterial clearance in the presence of appropriate antimicrobial therapy. In animals treated with ceftazidime, blood ( Fig. 1 ) and organ colony counts (data not shown) in the anti-CD14 antibody treated animals were similar to, or lower than, those in the isotype control group at all time-points. However, the results of this study also confirm previous reports that anti-CD14 strategies adversely affect bacter-ial clearance in the absence of antimicrobial therapy. Significantly higher levels of bacteremia, as measured in serial blood cultures and quantitative bacterial loads in target tissues, were evident in animals receiving the anti-CD14 antibody without ceftazidime in comparison to all other groups.
If these results can be extrapolated to human bacterial sepsis, the implications are clear. In patients with infection, anti-CD14 monoclonal antibodies should be administered in conjunction with appropriate antimicrobial therapy directed against the infecting micro-organism.
PREVIOUS STUDIES IN HEALTHY SUBJECTS
As reported previously, two IC14 clinical studies in healthy subjects have been completed. 15, 16 One study assessed the safety and pharmacology of single i.v. doses of IC14 ranging from 0.03-4 mg/kg in healthy subjects. The results of this study indicated that these doses of IC14 were well tolerated. 16 In a second study, 16 healthy subjects were challenged with 4 ng/kg of LPS after a single administration of 1 mg/kg IC14 or placebo. The results of this study showed that pretreatment with IC14 significantly attenuated the release of cytokines (TNF-a, IL-6, IL-10) and markers of endothelial cell activation (von Willebrandt Factor, soluble E-selectin) in response to LPS relative to placebo. 15 In addition, IC14 attenuated LPS-induced neutrophilia as well as the incidence and severity of 'flulike symptoms. Finally, IC14 also delayed the release of sTNFR1 and IL-1ra.
Recent follow-up reports from this study have described the effects of IC14 pretreatment on chemokine release, 17 fibrinolysis, and coagulation activation 18 in response to low-grade endotoxemia. IC14 diminished the release of the chemokines IL-8 and MCP-1 (both in plasma and cell associated), and MIP-1b (plasma) but not MIP-1a (plasma) in response to LPS. IC14 pretreatment also attenuated LPS-induced fibrinolysis without influencing coagulation. The results of these studies suggest that chemokine release is mediated, in part, by CD14 and that coagulation activation may have a different threshold for initiation or occur by a CD14-independent pathway.
SAFETY AND PHARMACOLOGY STUDY IN PATIENTS

WITH SEVERE SEPSIS
A phase 1 clinical study was conducted in patients with severe sepsis. 19 The objectives of this study were to assess the safety and pharmacology of single and repetitive doses of IC14. Although the study was not sufficiently powered to detect differences in efficacy, 28-day all-cause mortality and multiple organ dysfunction (MOD) scores were recorded. The study was conducted at 6 institutions in The Netherlands and Germany. Written informed consent was obtained from all subjects, and the study was approved by each institution's ethics committee.
A total of 40 patients with severe sepsis (10 per group; 8 IC14/2 placebo) were randomized to one of four IC14treatment groups or placebo in this double-blind, placebocontrolled trial. Two treatment groups received single doses of IC14 (1 mg/kg or 4 mg/kg). The remaining two treatment groups received 4 daily doses of IC14 (4 mg/kg or 4 mg/kg x 1 day followed by 2 mg/kg x 3 days). All treatments were administered i.v. over 60 min.
Patients over 18 years of age meeting the ACCP/SCCM Consensus Conference definition of severe sepsis were eligible for study participation. 20 Eligible patients had clinical evidence of infection within 48 h of enrolment, evidence of a systemic inflammatory response (2 or more SIRS criteria), and evidence of either sustained hypotension or organ dysfunction resulting from SIRS, and were evaluated for 28 days. In addition, all patients needed to receive parenteral antimicrobial therapy to be eligible for the study.
Treatment groups were similar at baseline for patient age, gender, and MOD score. No treatment-related increases in the incidence of secondary infection or death were noted in severe sepsis patients treated with IC14 ( Table 1 ). The highest number of deaths occurred in the 4 mg/kg single-dose IC14 treatment group. This group also showed the greatest disease severity at study entry evidenced by a higher baseline APACHE II score relative to placebo and other IC14 treatment groups.
The results from analyses of adverse events and clinical laboratory data suggest that both single and repetitive dose regimens of IC14 were well tolerated and not antigenic. Previous toxicology studies in cynomolgus monkeys showed increased mixed cell infiltration in the iris and ciliary body after treatment with IC14. 16 To address the potential risk of ocular infiltration in severe sepsis patients treated with IC14, slit-lamp ophthalmoscopy was performed on all patients daily during the first week after treatment. No treatment-related increases in infiltrating cells were found.
The relationship between serum IC14 concentration and monocyte CD14 receptor saturation after a single IC14 administration was markedly different in severe sepsis patients in comparison to healthy subjects or healthy subjects challenged with LPS. IC14 serum concentration and saturation of CD14 receptors were determined using ELISA and flow cytometric analysis, respectively. The EC 50 for monocyte CD14 saturation after a single administration of IC14 was similar in healthy subjects (0.34 ± 0.020 mg/ml) and subjects challenged with LPS (0.27 ± 0.073 mg/ml). However, the EC 50 in severe sepsis patients treated with a single dose of IC14 was markedly higher (0.99 ± 0.076 mg/ml).
Studies with IC14, a chimeric monoclonal antibody directed against human CD14 387 The shorter duration of CD14 saturation by IC14 observed in severe sepsis patients relative to healthy subjects may be at least partially related to increased IC14 clearance in these patients. Clearance of IC14 in severe sepsis patients was markedly higher in severe sepsis patients treated with 4 mg/kg IC14 (12.0 ml/kg/h in severe sepsis patients versus 2.1 ml/kg/h in healthy subjects) or 1 mg/kg IC14 (10.7 ml/kg/h in severe sepsis patients versus 6.4 ml/kg/h in healthy subjects).
In the repetitive dose groups, sustained and accumulating concentrations of IC14 were observed in the serum of severe sepsis patients treated with IC14 daily for 4 consecutive days. The initial dose of 4 mg/kg i.v. administered to both repetitive dose groups resulted in peak serum concentrations of 50-60 mg/ml which decreased over 24 h (Fig. 2) . The terminal elimination half-life of the 4 mg/kg dose in patients receiving repetitive doses was estimated to be ~20 h after the fourth dose of IC14. Patients receiving 3 subsequent daily doses of 2 mg/kg showed sustained serum concentrations of ~18 mg/ml during the treatment period. However, patients receiving 3 subsequent daily doses of 4 mg/kg had serum concentrations that increased from ~18 mg/ml tõ 72 mg/ml over the treatment period. Higher IC14 serum concentrations during the treatment period in the 4 mg/kg x 4 dose group did not result in a concentration-related marked increase in the duration of maximal monocyte CD14 receptor saturation by IC14. Serum IC14 concentrations at the end of the treatment period were 4-fold higher in the 4 mg/kg x 4 day repetitive dose group compared to the 4 mg/kg x 1 day followed by 2 mg/kg x 3 repetitive dose group. However, the duration of maximal (> 80%) CD14 saturation by IC14 in the 4 mg/kg x 4 repetitive dose group was only 1 day longer than the 4 mg/kg x 1 day followed by 2 mg/kg x 3 repetitive dose group (Fig. 3) .
Serum concentrations of the soluble CD14 isoform increased in response to IC14 treatment in a dose-related manner. This response was also seen in previous trials conducted in healthy subjects. 15 After a single 4 mg/kg dose of IC14, soluble CD14 concentrations in serum increased to similar levels in both severe sepsis patients and healthy subjects. However, in severe sepsis patients, this increase occurred earlier than in healthy subjects. Peak soluble CD14 concentration in severe sepsis patients occurred within 24 h of dosing ( Fig. 4) . In healthy subjects, however, peak soluble CD14 concentration was observed 72 h after dosing.
The likely implications of increased sCD14 release in response to IC14 treatment in patients with severe infection are uncertain. Soluble CD14 concentrations have been reported to correlate with increased disease severity in patients with sepsis. 21, 22 In contrast, exogenously administered soluble CD14 has been shown to prevent endotoxin-mediated shock in mice. 23 In addition, the results of a recent clinical study suggest that increased sCD14 may be associated with greater survival in patients with severe sepsis. 24 No differences in mortality were observed in any IC14 treatment group compared to placebo. This is to be expected given the small sample size of this study.
There were no significant decreases from baseline in the concentrations of pro-inflammatory cytokines, soluble E-selectin, or acute phase proteins in patients receiving placebo. In patients receiving single doses of 1 mg/kg or 4 mg/kg of IC14, significant decreases from baseline were observed in the concentrations of procalcitonin and IL-6, respectively, while repetitive doses of IC14 significantly decreased from baseline the concentrations of IL-6 and IL-10.
MOD score in IC14-treated patients improved as a function of receptor occupancy (P < 0.06). The trend toward improvement in MOD score was evident in the repetitive dose IC14 groups when compared to placebo (Fig. 5 ).
CONCLUSIONS
Taken together, the results from clinical studies of IC14 demonstrate that this chimeric monoclonal antibody diminishes the systemic inflammatory response directed against LPS and may have potential as a treatment to prevent organ dysfunction in patients with severe sepsis. Furthermore, IC14 treatment was generally well tolerated in both healthy subjects and severe sepsis patients and did not increase the incidence of secondary infections. Analysis of pharmacology data indicates that higher doses of IC14 are required to saturate membrane-bound CD14 receptors in patients with severe sepsis effectively than in healthy subjects. Finally, the results of non-clinical studies indicate that IC14 should only be administered with concurrent antimicrobial therapy in patients with infection.
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